FDA Career Scientists Briefing Documents (Released Monday-Tuesday, June 29-30): None of the Seven Peptides Has Sufficient Evidence for 503A Bulks List Eligibility, Citing Immunogenicity Adverse Events, Heavy-Metal Contamination, Microbial Contamination, and Mislabeled Contents in Compounding-Channel Products
FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) meeting, concluding that none of the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The briefing flagged four recurring concerns: limited or inadequate safety data; characterization and impurity concerns; lack of evidence of historical use in compounding meeting bulks-list criteria; and potential immunogenicity risk based on FDA adverse event data showing immune reactions to peptide preparations. The agency also presented data on product-quality failures observed in compounding-channel preparations, including heavy-metal contamination, microbial contamination, and mislabeled contents (some vials testing well below or above the labeled peptide concentration). The conclusion directly contradicts HHS Secretary RFK Jr.'s public position that the Category 2 removals (effective April 23, 2026) were meant to clear the path for 503A bulks list addition. Coverage ran across NBC News, NPR (syndicated to KPBS, Houston Public Media, WLRN, KGOU, HPPR, STLPR), Washington Post, and STAT News. The briefing is the most substantive regulatory development on the seven peptides since the April Federal Register notice.